Clinical Trial Update: Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of Gemzar (gemcitabine) in patients with recurrent or refractory bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: University of Pittsburgh | Conditions: Bladder Cancer | Phase 1 | Status: WITHDRAWN